�GammaCan International, Inc. (OTCBB: GCAN), a developer of proprietary immunotherapies for the treatment of melanoma and other cancers, announced further progress in its VitiGam� development program. In cookery for its upcoming IND submission for VitiGam�, the Company successfully completed extra experiments victimisation its established mouse melanoma model. These studies demonstrate a dose response of tumors (human melanoma cells) when treated with IgG preparations derived from vitiligo donors. In addition, the Company has conducted a meta-analysis (a statistical analysis of a large number of experiments) based on a series of antecedently announced studies with its mouse melanoma model. The results of this meta-analysis further confirm the effectuality against melanomas of IgG preparations derived from vitiligo donors.
Using the A375 human malignant melanoma cell communication channel in SCID mice, the Company demonstrated that vitiligo-derived IgG preparations can prevent the growth of melanomas in a dose dependent manner. In these studies, mice with subcutaneously induced melanomas were treated with varying concentrations of vitiligo-derived IgG preparations and compared to saline treated mice. At higher doses, vitiligo-derived IgG preparations reduced neoplasm sizes by fifty percent and greater when compared to turn down doses.
The Company likewise conducted a meta-analysis to further confirm the overall effectiveness of vitiligo-derived IgG preparations against melanoma cells. This analysis revealed a specific and highly statistically significant inhibition of neoplasm growth in mice treated with vitiligo-derived IgG preparations. Specifically, the Company ascertained that deuce separate pools of vitiligo-derived IgG preparations were able to inhibit tumor growth in a highly statistically significant mode (p=0.006) compared to control mice receiving saline. In gain, this analysis substantiated that anti-melanoma effects are specific to vitiligo-derived IgG preparations. Tumors in mice treated with vitiligo-derived preparations were significantly smaller (p=0.043) when compared to tumors in mice treated with IgG preparations from non-vitiligo donors.
Steven Katz, Chairman of the Board and President of GammaCan aforementioned, "These analyses confirm the validity of our anti-melanoma program. Using our models, we have repeatedly demonstrated that vitiligo-derived IgG preparations can foreclose tumor growth. Further, we have observed a dose response to vitiligo-derived IgG-based therapy." Mr. Katz further commented that, "These positive results keep to retain us on track to file our IND with the U.S. Food and Drug Administration in the near condition."
About GammaCan
GammaCan develops proprietary immunotherapy and related to approaches to treat malignant melanoma and other cancers. GammaCan's patented platform technology is based on the employment of IgGs (gamma-immunoglobulins), a safe, comparatively non-toxic human plasma-derived product used to treat a variety of immune deficiencies and autoimmune diseases. In cancer, IgG-based therapies work by strengthening the patient's immune system. Many experts currently view immunotherapy as a future alternative to chemotherapy. The Company's star drug nominee, VitiGam�, targets Stage III and Stage IV melanoma for which no effective treatment currently exists. In August 2007, VitiGam� standard Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the intervention of Stage IIB to Stage IV metastatic malignant melanoma. For more than information around GammaCan, visit http://www.GammaCan.com.
About VitiGam�
VitiGam� is a first-in-class IgG-based anti-cancer immunotherapy being highly-developed for the treatment of Stage III and Stage IV malignant melanoma. GammaCan is planning to submit its Investigational New Drug Application (IND) for VitiGam� to the FDA in the near next. The Company expects to commence human clinical trials shortly thereafter. VitiGam� is an IgG-based product manufactured from the plasma of donors with Vitiligo, a benign skin condition poignant up to 2% of the general population. Studies have shown that this "enriched" IgG formulation contains potent anti-melanoma activity. Based on these studies, GammaCan expects VitiGam� to put up specific anti-melanoma activity against melanoma cells, as well as nonspecific anti-cancer activity.
About Melanoma
Melanoma is a deadly form of skin cancer. According to the American Cancer Society, melanoma accounts for some 4% of all skin cancers just causes about 75% of all skin cancer-related deaths. An estimated 62,500 people testament be diagnosed with metastatic melanoma (Stage III and Stage IV) in 2008; the prognosis is poor since no effective treatment currently exists. These patients have a median endurance time of 8.5 months and a 5-year survival pace of less than 10%. There has been minuscule change in these results for in excess of 25 age. The incidence of melanoma has increased more speedily than whatsoever other crab during the past 10 years. The last dose to treat patients with metastatic malignant melanoma was approved by the FDA over 30 days ago.
Safe Harbor Statement
Statements in this squeeze release that are non purely historic are modern statements. Forward-looking statements in this press out release include statements regarding: the commercialisation of antineoplastic immunotherapies and the Company's efforts to develop therapies to promote the immune systems of cancer patients by the use of IgG-based therapy. Actual outcomes and the Company's literal results could differ materially from those in such forward-looking statements. Factors that could causal agency actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technology; the inability to hire set aside staff to develop the technology; unlooked-for technical difficulties in development the applied science; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise preferred for consumers; the unfitness to market a product; all of which could, among other things, detain or prevent product release, as well as other factors explicit from time to time in GammaCan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press outlet should be read in conjunction with GammaCan's periodic filings with the SEC, which are incorporated herein by acknowledgment. The advanced statements contained herein are made entirely as of the date of this press release and GammaCan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
http://www.GammaCan.com
More information
